The largest database of trusted experimental protocols

11 protocols using rantes

1

ELISA Analysis of Inflammatory Factors in BV-2 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
BV-2 cells were treated for 24 h and then supernatants from controls (dH2O only), from cells treated with GLE (0.5 mg/ml) only, LPS only (1.0 μg/ml), and GLE (0.5 mg/ml) + LPS (1.0 μg/ml) (where LPS was added after 1 h incubation with GLE), were used in the assay. Specific ELISAs (RayBiotech, Norcross, GA, USA) were performed using G-CSF (Cat# ELM-G-CSF), IL1α (Cat# ELM-IL1a), MCP-5 (Cat# ELM-MCP5), MIP3α (Cat# ELM-MIP3a), and RANTES (Cat# ELM-RANTES) following manufacturer’s instructions and as previously described (Mendonca et al., 2017 (link)). Briefly, 100 μl of supernatant from samples and standards were added to 96 well plates pre-coated with the capture antibody. After incubation, 100 μl of prepared biotinylated antibody mixture was added to each well and incubated for 1 h. The mixture was then decanted, and streptavidin solution (100 μl) was placed in each well and incubated. Substrate reagent (100 μl) was then added to each well for 30 min, followed by the addition of stop solution (50 μl). Data were quantified by optical density at 450 nm.
+ Open protocol
+ Expand
2

ELISA-based Cytokine Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
RANTES (RayBiotech), IL‐1β and IL‐6 (eBioscience) concentrations in cell culture media and mouse serum were measured using Enzyme‐linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions. The plates were measured at 450 nmol/L using an Epoch microplate spectrophotometer (BioTek Instruments). The concentrations of RANTES, IL‐1β and IL‐6 in the samples were determined by standard curves.
+ Open protocol
+ Expand
3

Quantification of Allergy Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Concentrations of eotaxin, IL-4, IL-5 (BD Pharmingen, CA, USA), RANTES (RayBiotech Inc., GA), and IL-13 (R&D Systems, Minneapolis, MN) in BALF were quantified using sandwich EIA kits according to the manufacturer's instructions. Similarly, the serum level of total IgE was quantified with a commercially available EIA kit (BD Pharmingen, CA, USA).
+ Open protocol
+ Expand
4

Cytokine Profiling in Synovial Fluid and Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell-free primary RA synovial fluid and plasma from healthy blood donors were used for detecting IL6 (BD OptEIA), IL8 (BD OptEIA), IL-17 (peptrotech), TNFα (Pierce-endogen) and RANTES (Ray Biotech) by the BD OptEIA enzyme-linked immunosorbent assay (ELISA) Kit following the manufacturers’ protocol. Briefly, non-tissue culture treated 96-well plates (Becton Dickson) were coated with capture antibody diluted in coating buffer (eBioscience) and incubated overnight at 4°C. PBS (Mideatech, Inc.) 10% FBS (Atlanta Biologicals) was used for blocking and as assay diluent as specified in the protocol. All washes during the protocol were performed with a Bio-Rad wash machine (Model 1575 Immunowash) using PBS with 0.5% Tween-20 (Sigma). After adding substrate, a color reagent TMB substrate also from BD biosciences, samples were stopped with the TMB stop solution (Kirkegaard and Perry Labs). Plates were read in a Spectramax PLUS 384 spectrophotometer at 450 nm with a background subtraction wavelength of 570 nm.
+ Open protocol
+ Expand
5

Quantifying IL-29 and RANTES Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
IL-29, ELISA Ready-Set-Go (eBioscience, San Diego, CA) and RANTES (RayBiotech, Norcross, GA) enzyme-linked immunosorbent assays (ELISAs) were performed as per the manufacturer's protocol.
+ Open protocol
+ Expand
6

Macrophage Response to Tumor Exosomes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine macrophage RAW 264.7 cells were seeded at a density of 104 in each chamber of an 8 well-chambered slide, allowed to adhere overnight, and subsequently treated or left untreated. Treatment regimens were a) 100 ng LPS for 24 hours (positive control), b) untreated 4T1-derived exosomes, c) HT treated 4T1-derived exosomes, d) untreated EMT-6-derived exosomes, and e) HT treated EMT-6-derived exosomes. The exosome-treated sets of cells were exposed to 1×106 vesicles for 24 hours. The RAW 264.7 supernatant was collected for ELISA analysis of IL-10, TNF-α, and RANTES according to the manufacturer’s instructions (RayBiotech, USA).
+ Open protocol
+ Expand
7

Cytokine Secretion Analysis in TNF-α-Treated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Following 24-hour coincubation with 10 ng/mL TNF-α and increasing concentrations of DMPF-1, spent media was collected and stored at −80°C prior to chemokine immunoassay. The concentrations of MCP-1, IL-8, eotaxin-1 (BD Pharmingen, USA), RANTES, and GRO-α (RayBiotech Inc., GA) were quantified with commercially available sandwich ELISA kits. All assays were conducted according to the manufacturer's instructions.
+ Open protocol
+ Expand
8

Anti-CD20 Antibody Modulation of B Cell-Fibroblast Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
The B-lymphocyte depletion effect was mediated by anti-CD20 monoclonal antibody rituximab (RTX, Roche, Shanghai, China). IGF-1R binding protein was used to block the IGF-1R pathway. CpG oligodeoxynucleotides were used to stimulate B lymphocyte activity. An MTS assay (Promega, USA) was used to detect cell proliferation activity in cells treated with different concentrations of RTX (1 mg/mL, 0.8 mg/mL, 0.6 mg/mL, 0.4 mg/mL or 0.2 mg/mL), the IGF-1 binding protein, or CpG. On day 1 of co-culturing orbital fibroblasts with B lymphocytes, 1 mg/mL RTX, 5 µL/mL IGF-1 binding protein, and 1 µg/mL CpG were added to the medium, according to the results of the MTS assay (data not shown). A negative control group was created for each drug treatment. The supernatant of co-cultured cells was collected after 48 h and centrifuged at 1,000 g for 10 min to remove debris. The expression levels of interleukin-6 (IL-6, RayBiotech, USA) and RANTES (RayBiotech, USA) were quantified in triplicate via an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s protocols.
+ Open protocol
+ Expand
9

Cytokine Analysis in Stroke Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
For cytokine analysis, 2 months old males (6 animals per group) were used. At 1, 4 or 7 days after stroke the animals were anesthetized and their blood flushed out with 20ml cold PBS via transcardial perfusion. Then, the brains were harvested and cut to 1mm thick coronal sections. After a quick TTC staining, infarct core (approximate 2 by 2 mm) was dissected out and frozen with liquid nitrogen. Since we found that the most anterior sections, containing the striatum area, produced the most comparable size between the cortical strokes in each type of model, we limited the cytokine analysis to the first half of the brain. For cytokine analysis, brain tissue was subject to multiplex ELISA analysis through the Quantibody Mouse Cytokine Array for the following cytokines/chemokines: bFGF, BLC, CD30L, eotaxin, eotaxin-2, FasL, G-CSF, GM-CSF, ICAM, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-13, IL-15, IL-17, IL-21, KC, leptin, LIX, MCP-1, MCP-5, M-CSF, MIG, MIP-1a, MIP-1g, PF-4, RANTES, TARC, TCA-3, TNF RI, TNF RII, TNFα (RayBiotech Inc.).
+ Open protocol
+ Expand
10

Plasma Biomarker Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma biomarkers were assayed by enzyme-linked immunosorbent assay. Kits were purchased from the following sources: neuropeptide Y (NPY), RANTES (Regulated on activation, normal T-cell-expressed and secreted), and E-selectin from Ray Biotech (Norcross, GA); serotonin from Enzo Life Sciences Inc (Farmingdale, NY); CS846 (aggrecan chondroitin sulfate 846) from IBEX Pharmaceuticals Inc (Montreal, Quebec, Canada); and CTX-II (C-terminal telopeptide of type II collagen) from Immunodiagnosticsystems, IDS Inc (Gaiersburgh, MD). All samples were assayed in duplicate and averaged following the manufactures’ instructions and reported as concentration (ng/ml).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!